U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07137481) titled 'Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies' on Aug. 15.

Brief Summary: To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.

Study Start Date: Feb. 28, 2026

Study Type: INTERVENTIONAL

Condition: Hematological Malignancies

Intervention: DRUG: C9/CD5CAR/IL-15 NK cells

Given PO or IV

DRUG: Rituximab

Given by IV

DRUG: Fludarabine

Given by IV

DRUG: Cyclophosphamide

G...